Effects of acute or chronic omega-3 and omega-6 polyunsaturated fatty acid treatment on behavioral, neuroendocrine and cytokine changes elicited by exogenous interleukin-1beta challenge.
Chronic omega-3 or omega-6 polyunsaturated fatty acid (n-3; n-6 respectively) treatment attenuated human interleukin-1beta (hIL-1beta; 5.0 microg/kg)-elicited rise of circulating ACTH levels and attenuated the sickness behavior and locomotor suppression elicited by the cytokine. Furthermore, hIL-1beta markedly elevated circulating levels of plasma IL-6, an effect attenuated by n-3, but not n-6 treatment. Such protective effects were not evident upon short-term (3 day) n-3 exposure. These results demonstrate that long-term administration of either n-3 or n-6 confers protection against several neuroendocrinological, immunological and behavioral actions of hIL-1beta challenge, although in general the effects of n-3 were more pronounced.
Miguelez
Maïa
M
Institute of Neuroscience, University of Carleton, Neuroscience Building, Rm 333, Ottawa, Ontario, Canada K1S 5B6.
Anisman
Hymie
H
Weber
Jean-Michel
JM
Merali
Zul
Z
D000324:Adrenocorticotropic Hormone / Q000097:blood; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001831:Body Temperature / Q000187:drug effects; D003345:Corticosterone / Q000097:blood; D005227:Fatty Acids / Q000378:metabolism; D015525:Fatty Acids, Omega-3 / Q000494:pharmacology*; D043371:Fatty Acids, Omega-6 / Q000494:pharmacology*; D053583:Interleukin-1beta / Q000494:pharmacology*; D015850:Interleukin-6 / Q000097:blood*; D008099:Liver / Q000378:metabolism; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D015213:Neuroimmunomodulation / Q000187:drug effects; D009490:Neurosecretory Systems / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley
D005227:Fatty Acids; D015525:Fatty Acids, Omega-3; D043371:Fatty Acids, Omega-6; D053583:Interleukin-1beta; D015850:Interleukin-6; D000324:Adrenocorticotropic Hormone; D003345:Corticosterone